C.R. Bard (NYSE:BCR) said yesterday that the FDA approved a supplemental investigational device exemption to change the main 6-month endpoint in the clinical trial of a new version of its Lutonix drug-coated balloon in treating below-the-knee peripheral arterial disease. Murray Hill, N.J.-based Bard in October 2014 won pre-market approval from the FDA for the Lutonix 035 DCB for PAD lesions above the […]
C.R. Bard
Bard Q2 earnings top estimates
C.R. Bard (NYSE:BCR) released its 2nd quarter earnings yesterday, topping the Street’s expectations and adjusting its outlook for the rest of the year. The Murray Hill, N.J.-based company reported profits of $159.2 million, or $2.11 per share, on sales of $931.5 million for the 3 months ended June 30. That’s a significant turnaround from the $54.7 […]
U.S. companies starting to see relief from pains of strong dollar
(Reuters) — The sluggish U.S. economy is proving to be a relief for U.S.-based companies struggling under the weight of the strong dollar and could lead to more positive earnings surprises in the weeks ahead. Companies including Whirlpool (NYSE:WHR), Johnson & Johnson (NYSE:JNJ) and Xerox (NYSE:XRX) have told investors over the last 2 weeks that they […]
Bard sees shares rise on Q1 beat
C.R. Bard (NYSE:BCR) today released its 1st quarter earnings, handily topping the Street’s expectations for revenue and earnings per share and seeing shares rise in after hours trading. The company reported profits of $116.2 million, or $1.54 per share, on sales of $873.5 million for the 3 months ended March 31, 2016. That amounts to […]
C.R. Bard settles clutch of pelvic mesh lawsuits
A West Virginia federal judge yesterday dismissed nearly 150 product liability lawsuits brought against C.R. Bard (NYSE:BCR) over its pelvic mesh products, after an appeals court earlier this year upheld a $2 million verdict against the company in another suit. Judge Joseph Goodwin of the U.S. District Court for Southern West Virginia, who’s overseeing the multi-district […]
Bard touts data from Lutonix head-to-head study against MDT’s In.Pact
C.R. Bard (NYSE:BCR) subsidiary Bard Peripheral Vascular touted results showing no significant difference in a study pitting its Lutonix DCB against Medtronic‘s (NYSE:MDT) In.Pact DCB in treating patients with complex femoropopliteal lesions. Clinical data from the investigator-sponsored retrospective, single-center study was presented during the Leibzig International Course in Leipzig, Germany last month. The study reported […]
Fonar taps MR scan inventor and founder’s son as CEO | Personnel Moves
Fonar Corp (NSDQ:FONR) said yesterday it named Timothy Damadian, son of magnetic resonance scanning inventor and company founder Dr. Raymond Damadian, as its new president and CEO. The younger Damadian worked with Fonar for 16 years, eventually becoming veep of operations. He formed Fonar subsidiary Health Management Corporation of America, which manages medial and diagnostic […]
Boston Scientific, Bard escape joint pelvic mesh trial
Boston Scientific (NYSE:BSX) and C.R. Bard (NYSE:BCR) yesterday won the 1st trial in a pelvic mesh lawsuit against 2 companies after a Kansas City jury voted 10-2 that their implants were not defective and didn’t cause plaintiff Eve Sherrer’s injuries. Sherrer alleged that Bard’s Align and Boston Scientific’s Solyx products used a polypropylene mesh that reacts to tissue by […]
Bard’s Q4 earnings top estimates
C.R. Bard (NYSE:BCR) yesterday beat the consensus estimate for its 4th-quarter earnings. Murray Hill, N.J.-based Bard posted profits of $136.3 million, or $1.79 per share, on sales of $870.8 million for the 3 months ended Dec. 31, 2015, for a bottom-line gain of 1.6% on sales growth of 0.4% compared with Q4 2014. Adjusted to […]
Johnson & Johnson to pay $120m in 1st mesh settlement
Johnson & Johnson (NYSE:JNJ) is making the 1st move in settling thousands of lawsuits from women who claim the company’s vaginal-mesh inserts caused organ damage and serious pain, paying $120 million to settle the 1st 2,000 to 3,000 suits, according to Bloomberg. The company still faces over 40,000 suits related to vaginal meshes, and its […]
C.R. Bard closes $181m Liberator Medical buy
C.R. Bard (NYSE:BCR) said yesterday that it closed the $181 million acquisition of Liberator Medical (NYSE:LBMH), a direct-to-consumer distributor of durable medical equipment. The deal called for Murray Hill, N.J.-based Bard to pay $3.35 per share for Liberator, a 36% premium over Liberator’s 90-day average closing price through Nov. 19, 2015, the day before the deal was […]